IPO - Advanced Biomed Inc.

Form Type: 8-K

Filing Date: 2025-03-10

Corporate Action: Ipo

Type: New

Accession Number: 000157587225000240

Filing Summary: On March 5, 2025, Advanced Biomed Inc. entered into an underwriting agreement with Craft Capital Management LLC for its initial public offering (IPO) of 1,640,000 shares of common stock at a price of $4.00 per share. The underwriter was granted a 45-day option to purchase an additional 246,000 shares to cover any over-allotments. The offering was completed on March 7, 2025, and the shares commenced trading on The Nasdaq Capital Market under the ticker symbol 'ADVB' on March 6, 2025. The Company issued warrants to purchase 98,400 shares at $5.00 to the representative as compensation. The documentation includes various attached exhibits and disclaimers pertaining to regulatory compliance and offering terms.

Form Type: 424B4

Filing Date: 2025-03-06

Corporate Action: Ipo

Type: New

Accession Number: 000157587225000219

Filing Summary: Advanced Biomed Inc. is offering 1,640,000 shares of Common Stock at a price of $4.00 per share through an underwritten offering. This is a primary offering, and there has been no public market for the Common Stock prior to this point. The company is a holding company incorporated in Nevada, with operations managed through its subsidiaries in Taiwan, Hong Kong, and Mainland China. The securities are being registered under Rule 424(b)(4) with approval obtained for listing on the NASDAQ Capital Market under the ticker symbol 'ADVB.' Furthermore, there are legal and operational risks involved due to potential regulatory actions by the Chinese government, affecting business operations and investments. This prospectus details the business structure, the offering process, and outlines the risks associated with operations in China.

Form Type: 424B4

Filing Date: 2025-03-06

Corporate Action: Ipo

Type: Update

Accession Number: 000157587225000222

Filing Summary: Advanced Biomed Inc. filed a prospectus supplement for an initial public offering (IPO) to offer up to 1,640,000 shares of common stock at a price of $4.00 per share. This offering is made under registration statement No. 333-272110, which was filed with the SEC. The company anticipates net proceeds of approximately $5.14 million, with plans to utilize 60% for in vitro diagnostics clinical research and development, 20% for marketing and sales, and 20% for general working capital. The total shares outstanding before the offering were 20,000,000, expected to increase to 21,640,000 following the offering. A lock-up agreement restricts the company’s issuance of securities for 180 days post-offering without underwriter consent. Furthermore, an over-allotment option allows underwriters to purchase an additional 246,000 shares to cover over-allotments. The listing will occur on the Nasdaq Capital Market under the symbol 'ADVB'.

Form Type: CORRESP

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: New

Accession Number: 000157587225000143

Filing Summary: Advanced Biomed Inc. has requested the acceleration of the effectiveness of its registration statement on Form S-1 (File No. 333-272110) to become effective at 4:30 p.m. on February 11, 2025. This request was made by Craft Capital Management LLC, representing itself and other underwriters, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933. The underwriters intend to distribute the preliminary prospectus dated February 7, 2025, to a wide range of potential investors, and have confirmed their compliance with Rule 15c2-8 under the Securities Exchange Act of 1934.

Form Type: S-1/A

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: Update

Accession Number: 000157587225000138

Filing Summary: On February 7, 2025, Advanced Biomed Inc. filed Amendment No. 16 to its Form S-1 registration statement with the SEC. The amendment is part of the process for the proposed IPO of 1,875,000 shares of common stock, priced between $4.00 to $6.00 per share. The company seeks to list its shares on the Nasdaq Capital Market under the symbol 'ADVB'. This registration statement includes two prospectuses: one for the primary offering and another for resale by selling stockholders. The contingencies of the offering are tied to listing on Nasdaq, and the filing indicates the potential for regulatory implications due to the company's operations in China, particularly under the scrutiny of the Chinese government regarding foreign investments and oversight of overseas offerings. The registration statement outlines risk factors associated with the company's business structure, regulatory compliance, and potential impacts from Chinese government policies.

Form Type: S-1/A

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: New

Accession Number: 000157587225000091

Filing Summary: Advanced Biomed Inc. filed its amendment No. 15 to Form S-1 registration statement on January 27, 2025, in preparation for its initial public offering (IPO) of 1,875,000 shares of common stock. The intended price range for the offering is $4.00 to $6.00 per share, with plans to list the common stock on the Nasdaq Capital Market under the symbol 'ADVB.' The company is incorporated in Nevada but operates primarily through subsidiaries based in Taiwan, Hong Kong, and Mainland China. The document outlines the regulatory environment that may affect the operations and value of the securities due to government interventions in China, particularly in light of new regulations governing cybersecurity and foreign investments. The registration will enable Advanced Biomed to raise capital and potentially expand operations, though successful listing on Nasdaq is contingent on regulatory approvals. The offering structure includes both a primary offering and a resale prospectus for shares held by certain stockholders. Significant risks are highlighted regarding the business environment in China and the complexity of regulatory approvals for foreign stock sales. There is uncertainty regarding compliance with various Chinese laws that could impact the company's financial performance and future offerings.

Form Type: S-1/A

Filing Date: 2025-01-07

Corporate Action: Ipo

Type: Update

Accession Number: 000157587225000012

Filing Summary: Advanced Biomed Inc. filed Amendment No. 14 to its Form S-1 Registration Statement on January 7, 2025, with the intention of offering 1,875,000 shares of Common Stock. The proposed offering price is between $4.00 to $6.00 per share, with a plan to list the stock on NASDAQ under the symbol 'ADVB'. The document outlines two types of prospectuses: a Primary Offering for initial investors and a Resale Prospectus for existing shareholders looking to sell their shares. There have been no public market transactions for the Common Stock prior to this offering. The filing indicates that Advanced Biomed is not currently an operating company but a holding entity registered in Nevada, with major operations in Taiwan and additional subsidiaries in Hong Kong and Mainland China. The company acknowledges potential regulatory challenges and emphasizes that the ongoing regulatory climate in China could impact its operations and securities offerings. The registration includes risk factors related to Chinese government controls that could affect its ability to operate and raise funds internationally.

Form Type: CORRESP

Filing Date: 2023-11-20

Corporate Action: Ipo

Type: Update

Accession Number: 000157587223001799

Filing Summary: Advanced Biomed Inc. submitted an amendment to the Registration Statement on Form S-1 in response to SEC comments dated November 6, 2023. This document addresses concerns regarding other expense disclosures, liquidity and capital resources, and intellectual property ownership within industry-academia cooperation agreements with National Taiwan University. The company detailed significant increases in other expenses and our cash deposit locations, also clarifying financing strategies involving known terms and amounts. The intellectual property rights related to the cooperation agreement were specified, granting ownership to the National Taiwan University while allowing Advanced Biomed to license and use created works.